Back to top
more

Horizon Pharma Public Limited Company (HZNP)

(Delayed Data from NSDQ)

$26.54 USD

26.54
1,058,972

+0.55 (2.12%)

Updated May 3, 2019 04:00 PM ET

After-Market: $26.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca's (AZN) Lupus Drug Saphnelo Gets Europe Nod

by Zacks Equity Research

AstraZeneca's (AZN) Saphnelo is the only new biologic to be approved in Europe in over a decade for patients with systemic lupus erythematosus.

Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

by Zacks Equity Research

Sector ETF report for PTH

Horizon (HZNP) Begins Enrollment in Rare Lung Disease Study

by Zacks Equity Research

Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.

Horizon (HZNP) Submits sBLA for Krystexxa Label Expansion

by Zacks Equity Research

Horizon (HZNP) files a supplemental biologics license application to the FDA for Krystexxa plus methotrexate to treat people living with uncontrolled gout.

Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

by Zacks Equity Research

Sector ETF report for PTH

Horizon Therapeutics (HZNP) Down 6.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Horizon (HZNP) Gets Positive CHMP Opinion for Uplizna in NMOSD

by Zacks Equity Research

The CHMP gives a positive opinion on, and recommends approval to Horizon's (HZNP) Uplizna for treating adult patients with neuromyelitis optica spectrum disorder.

Horizon's (HZNP) Q3 Earnings Beat Estimates, 2021 Guidance Up

by Zacks Equity Research

Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2021. The company lifts net sales guidance for 2021.

Horizon Therapeutics (HZNP) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 13.64% and 5.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Horizon Therapeutics (HZNP) is a Top-Ranked Momentum Stock: Should You Buy?

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Horizon Therapeutics (HZNP) Might Surprise This Earnings Season

by Zacks Equity Research

Horizon Therapeutics (HZNP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Charles River (CRL) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Robust demand for research models and the Vigene Biosciences buyout are likely to have contributed to growth for Charles River (CRL).

STERIS (STE) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Strong gains from the recent Cantel Medical buyout as well as the addition of a new Dental arm are expected to have contributed STERIS' (STE) Q2 performance.

Horizon Therapeutics (HZNP) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Horizon Therapeutics (HZNP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

If You Invested $1000 in Horizon Therapeutics 10 Years Ago, This Is How Much You'd Have Now

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

3 Reasons Why Growth Investors Shouldn't Overlook Horizon Therapeutics (HZNP)

by Zacks Equity Research

Horizon Therapeutics (HZNP) possesses solid growth attributes, which could help it handily outperform the market.

Biogen's (BIIB) Tofersen Reports Mixed Data From ALS Study

by Zacks Equity Research

Biogen's (BIIB) phase III study evaluating tofersen for ALS with SOD1 mutation fails to meet the primary endpoint of the study. However, the study shows signs of reduced disease progression with tofersen.

Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

by Zacks Equity Research

Sector ETF report for PTH

Anthem (ANTM) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Anthem's (ANTM) third-quarter results are likely to reflect gains from increased premiums, and strong membership growth across its Medicare and Medicaid businesses, partly offset by rising expenses.

This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

J&J (JNJ) Seeks Stelara Label Expansion in Juvenile Arthritis

by Zacks Equity Research

J&J (JNJ) files a regulatory application, seeking the label expansion of its inflammatory drug, Stelara, as a potential treatment of juvenile psoriatic arthritis.

Boston Scientific (BSX) Reports Data Backing Eluvia Stent

by Zacks Equity Research

The positive data demonstrated the superiority of Boston Scientific's (BSX) Eluvia stent compared to bare metal stents in treating patients with peripheral artery disease.

Fortress' (FBIO) Partner Meets Study Goal for Menkes Disease

by Zacks Equity Research

Cyprium Therapeutics, a partner company of Fortress Biotech (FBIO), reports positive data from two pivotal studies evaluating CUTX-101 in patients with Menkes disease.

The Zacks Rank Explained: How to Find Strong Buy Medical Stocks

by Zacks Equity Research

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Here's How Much a $1000 Investment in Horizon Therapeutics Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.